Poolbeg Pharma will trial its oral drug POLB 001 at six NHS hospitals to prevent cytokine release syndrome (CRS), a dangerous side-effect of cancer immunotherapy. The drug could improve patient safety and save healthcare systems millions by allowing treatment outside specialist centers.
Five NHS patients in England with severe lupus are in remission after receiving CAR T-cell therapy, a groundbreaking treatment that genetically modifies immune cells to reset the immune system, offering hope for a potential cure.
An AI-designed universal vaccine targeting SARS, MERS, and COVID-19 showed modest immune effects in a small, first-in-human trial, offering potential for future pandemic prevention.
A new experimental drug in a UK clinical trial aims to remove the "invisibility cloak" that cancer cells use to hide from the immune system. In early trials with 83 late-stage cancer patients, some saw significant tumor shrinkage, suggesting a new direction for cancer immunotherapy.
Adults are consuming bovine colostrum, the first milk mammals produce, for purported health benefits like improved gut health and immunity. While early research shows promise, experts caution that more studies are needed and lifestyle changes should be prioritized.
Diagnosed HIV positive at 22 in 1986, the author, now 62, is one of the rare 'elite controllers' who remain undetectable without antiretroviral drugs. He shares his journey of survival, survivor's guilt, and his involvement in research aiming for an HIV cure.
CAR T cell therapy, initially for cancer, shows promise for autoimmune diseases like MS. While offering hope, it carries risks and uncertainties regarding efficacy and long-term side effects, with costs also being a significant challenge.
Research suggests routine vaccines may reduce dementia risk via 'trained immunity', enhancing innate immune responses to prevent neuro-inflammation.
A new UK and US-based cancer trial, named Mighty, is set to recruit up to 60 children and young people with difficult-to-treat solid tumours. The study will use CAR T-cell immunotherapy to train immune systems to fight rare and aggressive cancers, offering a "real sense of hope" for new treatments.
